Alimera and Emory University sign agreement for ophthalmic treatment

The agreement gives Alimera the exclusive option to license a class of small molecule compounds, known as triphenylmethanes, as a potential treatment for ocular disorders such as diabetic retinopathy and the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition, which is known as geographic atrophy. This agreement is in addition to the September 2007 option to license the NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidase inhibitors for similar treatments.

If the option is exercised, Alimera will hold an exclusive worldwide license for the triphenylmethanes for ophthalmic indications. The agreement also includes an exclusive right to sublicense in ophthalmology and a exclusive option for non-ophthalmic use. Alimera will be responsible for both the development and commercialization of the compounds. Emory will receive milestone payments and royalties from net sales.

Cale Lennon, III, assistant director, Office of Technology Transfer, at Emory University, said: “The addition of the triphenylmethanes will provide Alimera and Emory with a unique class of therapeutic candidates to address the role of oxidative stress in ophthalmic diseases.”